Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.

JAMA Oncol. 2018 Dec 1;4(12):e184060. doi: 10.1001/jamaoncol.2018.4060. Epub 2018 Dec 13.

PMID:
30383140
2.

STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.

Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, Espat NJ, Junghans RP, Katz SC.

Oncogene. 2018 Aug 29. doi: 10.1038/s41388-018-0449-z. [Epub ahead of print]

PMID:
30158673
3.

Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer.

Ahmad A, Reha J, Saied A, Espat NJ, Somasundar P, Katz SC.

Hepatobiliary Surg Nutr. 2017 Jun;6(3):154-161. doi: 10.21037/hbsn.2016.08.08.

4.

Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression.

Guha P, Cunetta M, Somasundar P, Espat NJ, Junghans RP, Katz SC.

J Leukoc Biol. 2017 Aug;102(2):201-208. doi: 10.1189/jlb.5HI0716-322RR. Epub 2017 May 25.

PMID:
28546503
5.

Predictors of surgical non-referral for colorectal liver metastases.

Ahmad A, Reha J, Somasundar P, Espat NJ, Katz SC.

J Surg Res. 2016 Sep;205(1):198-203. doi: 10.1016/j.jss.2016.06.037. Epub 2016 Jun 21.

PMID:
27621019
6.

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, Junghans RP.

Clin Cancer Res. 2015 Jul 15;21(14):3149-59. doi: 10.1158/1078-0432.CCR-14-1421. Epub 2015 Apr 7.

7.

Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases.

Saied A, Katz SC, Espat NJ.

Hepatobiliary Surg Nutr. 2013 Apr;2(2):97-107. doi: 10.3978/j.issn.2304-3881.2012.12.07. Review.

8.

Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils.

Licata LA, Nguyen CT, Burga RA, Falanga V, Espat NJ, Ayala A, Thorn M, Junghans RP, Katz SC.

J Leukoc Biol. 2013 Oct;94(4):813-23. doi: 10.1189/jlb.0313137. Epub 2013 Jul 24.

9.

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor.

Katz SC, Burga RA, Naheed S, Licata LA, Thorn M, Osgood D, Nguyen CT, Espat NJ, Fletcher JA, Junghans RP.

J Transl Med. 2013 Feb 21;11:46. doi: 10.1186/1479-5876-11-46.

10.

Thermal tumor ablation therapy for colorectal cancer hepatic metastasis.

Munireddy S, Katz S, Somasundar P, Espat NJ.

J Gastrointest Oncol. 2012 Mar;3(1):69-77. doi: 10.3978/j.issn.2078-6891.2012.008.

11.

Feasibility of purely laparoscopic resection of locally advanced rectal cancer in obese patients.

Oyasiji T, Baldwin K, Katz SC, Espat NJ, Somasundar P.

World J Surg Oncol. 2012 Jul 16;10:147. doi: 10.1186/1477-7819-10-147.

12.

The effects of sorafenib on liver regeneration in a model of partial hepatectomy.

Kurniali PC, O'Gara K, Wang X, Wang LJ, Somasundar P, Falanga V, Espat NJ, Katz SC.

J Surg Res. 2012 Nov;178(1):242-7. doi: 10.1016/j.jss.2012.01.033. Epub 2012 Mar 29.

13.

Total laparoscopic distal pancreatectomy: beyond selected patients.

Boutros C, Ryan K, Katz S, Espat NJ, Somasundar P.

Am Surg. 2011 Nov;77(11):1526-30.

PMID:
22196669
14.

Laparoscopic spleen-preserving distal pancreatectomy in elderly subjects: splenic vessel sacrifice may be associated with a higher rate of splenic infarction.

Baldwin KM, Katz SC, Espat NJ, Somasundar P.

HPB (Oxford). 2011 Sep;13(9):621-5. doi: 10.1111/j.1477-2574.2011.00341.x.

15.

Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis.

Katz SC, Ryan K, Ahmed N, Plitas G, Chaudhry UI, Kingham TP, Naheed S, Nguyen C, Somasundar P, Espat NJ, Junghans RP, Dematteo RP.

J Immunol. 2011 Aug 1;187(3):1150-6. doi: 10.4049/jimmunol.1004077. Epub 2011 Jun 22.

16.

What, how, and when to offer nonresectional therapy for colorectal cancer liver metastases.

Boutros C, Espat NJ.

J Gastrointest Surg. 2011 Mar;15(3):420-2. doi: 10.1007/s11605-011-1428-7. Epub 2011 Jan 25. No abstract available.

PMID:
21264686
17.

T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gönen M, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH.

HPB (Oxford). 2010 Dec;12(10):674-83. doi: 10.1111/j.1477-2574.2010.00231.x.

18.
19.

Management of an incidental liver mass.

Boutros C, Katz SC, Espat NJ.

Surg Clin North Am. 2010 Aug;90(4):699-718. doi: 10.1016/j.suc.2010.04.005. Epub 2010 Jun 9. Review.

PMID:
20637942
20.

Omega-3 fatty acids: investigations from cytokine regulation to pancreatic cancer gene suppression.

Boutros C, Somasundar P, Razzak A, Helton S, Espat NJ.

Arch Surg. 2010 Jun;145(6):515-20. doi: 10.1001/archsurg.2010.91. Review.

PMID:
20566969

Supplemental Content

Loading ...
Support Center